Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults
Recently published NanoFlu(TM) preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains
Data from trial expected by the end of 2017
GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in older adults.
The trial is a randomized, observer-blinded, active comparator-controlled trial in approximately 330 healthy older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu compared to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD).
"The trial is designed to identify an immune response, characterized by hemagglutination-inhibiting (HAI) and neutralizing antibodies, that is similar to or better than Fluzone HD," said Gregory Glenn, M.D., President of Research and Development. "We will evaluate immunogenicity using HAI titers, which are the industry standard and an established surrogate marker of protection. Data from this trial may provide the basis to request accelerated approval for initial licensure of our NanoFlu vaccine.
"Our recent preclinical data further indicate NanoFlu elicits improved protective responses against drifted strains, which could be a key differentiating factor of the vaccine. Current influenza vaccine protection is typically limited to strain-specific immune responses. Strain mismatch or antigenic drift between seasonal vaccines and circulating influenza strains can lead to reduced protection."
"The data described in our recent Vaccine publication provided strong rationale for advancing our NanoFlu program into the clinic," said Stanley C. Erck, President and CEO. "Seasonal influenza remains a significant threat to older adults, with nearly three million infections and over 250,000 hospitalizations annually1. Our goal is to deliver a differentiated flu vaccine to the greater than $3 billion global seasonal influenza commercial market2 and we look forward to delivering clinical data from this trial by the end of the year."
About Accelerated Approval
Accelerated approval may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments.
Such an approval will be based on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit. More information on accelerated approval can be found here: https://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074794.htm
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
1. Average of 3 past seasons, 2010-2013; includes vaccine averted cases. C. Reed et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PLOS One. 2015, DOI:10.1371/journal.pone.0118369
2. PharmaPoint Seasonal Influenza Vaccines Global Drug Forecast and Market Analysis to 2025, October 2016
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2016 and the Report on Form 10-Q for the period ended June 30, 2017, both as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
This is a test from GlobeNewswire13.11.2018 23:54 | Pressemelding
LONDON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Senior Director, Global Head of GlobeNewswire Media Relations Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or David Didier Lislet Manager, GlobeNewswire Media Relations, EMEA Phone: +33 185 341 347
ELS Educational Services, Inc. Wins English Language School Award for Sixth Consecutive Year13.11.2018 23:20 | Pressemelding
ELS Educational Services, Inc. won the award for English Language School – USA at the UED Agency Awards of Turkey. This is the sixth consecutive year ELS has won the award. Princeton, New Jersey, Nov. 13, 2018 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE ELS Educational Services, Inc. won the award for English Language School – USA at the UED Agency Awards of Turkey. This is the sixth consecutive year ELS has won the award. The UED Agency Awards is the first competition of its kind that recognizes excellence among language schools and service providers in Turkey. Institutions are nominated then voted on by UED Member Agencies, who are the leaders of the international education consultancy sector in Turkey. “The ELS brand is stronger than ever in Turkey,” said Osman Akyuz, Director of Recruitment and Agent Support in Turkey. “We provide the best academic English in great locations and we have the most experienced instructors.” ELS was presented the award at a banquet at the Divan Otel / Ta
Doc re. GE Files Form 8-K13.11.2018 17:30 | Pressemelding
FAIRFIELD, Conn., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-k November 13, 2018 On November 13, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to RNS. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. http://www.rns-pdf.londonstockexchange.com/rns/2365H_1-2018-11-13.pdf CONTACT: GE Jennifer Erickson +001 646 682 5620 firstname.lastname@example.org This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visi
CloudGenix Named a Finalist in the 2018 CRN® Tech Innovator Awards13.11.2018 17:00 | Pressemelding
Company’s AppFabric Recognized in the 2018 Enterprise Networking Category SAN JOSE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CloudGenix announced today that CRN , ® a brand of The Channel Company, has been recognized as a finalist in the 2018 CRN Tech Innovator Awards. These annual awards honor standout hardware, software, and services that are moving the IT industry forward. In compiling the 2018 Tech Innovator Award list, CRN editors evaluated 300 products across 34 technology categories using several criteria, including technological advancements, uniqueness of features and potential to help solution providers solve end users' IT challenges. CloudGenix’s AppFabric took top honors in the Enterprise Networking category. CloudGenix AppFabric is a revolutionary software-defined wide area networking (SD-WAN) platform that allows businesses to integrate cloud and SaaS applications, create a secure application-defined fabric across any WAN transport, reduce operational cost and complexity
Atico Reports Reserves of 119 Million Pounds of Copper at the El Roble Mine13.11.2018 15:51 | Pressemelding
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) is pleased to announce the release of an updated NI 43-101 mineral resource and reserve estimate for the El Roble Mine located in Colombia. El Roble is currently in production at a rate of 850tpd and production guidance for the year is 20 million pounds of copper along with 9,850 ounces of gold in 2018. For the first three quarters of 2018, El Roble has produced 16 million pounds of copper and 8,400 ounces of gold or over 80% and 85% of annual forecast production for copper and gold respectively. “Our infill and mine vicinity exploration drilling at El Roble mine has been successful in replenishing mined resources since 2013. The maiden resource study at El Roble mine of 1.5 million tonnes of inferred resource has grown to 1.8 million tonnes of measured and indicated resources, while also having mined over 1 million tonnes of high-grade ore during
New VANTIQ Pronto Drives Modern Event-Driven Systems13.11.2018 15:00 | Pressemelding
VANTIQ Pronto Dynamic Advanced Event Broker™ enables organizations with real-time business responsiveness across enterprise, cloud and edge events PONTE VEDRA BEACH, Fla., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Today, at the nGage Enterprise Transformation Exchange Summit, VANTIQ announced VANTIQ Pronto, the industry’s first dynamic “Advanced Event Broker” (AEB). IT leaders from across the U.S. learned how Pronto is designed to deliver unique advantages for companies looking to power modern, event-driven applications with the real-time business responsiveness, intelligence and agility required for digital transformation initiatives. VANTIQ Pronto will be generally available to developers on November 30 at no charge for up to 2 million event messages in production per month. According to Gartner, “Application leaders engaged in digital transformation must include event-driven computing in their portfolio of skills and technology, including the key related responsibilities for event brokering
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom